[Discussion] the 503A advice in here is 2 years out of date
the 503A advice in here is 2 years out of date. I have gone back and forth on this for months.
The numbers the title promised, since a headline without them is worthless: 2 years. Everything below is context for those.
A 503A pharmacy compounds for an identified patient against a prescription. A 503B outsourcing facility registers with the regulator, may produce without patient-specific prescriptions, and is subject to current good manufacturing practice requirements. The two are governed differently and the difference is not cosmetic.
Compounded preparations are not approved products and carry no bioequivalence claim. That is a statement about regulatory category, not about quality.
That is everything I have. The rest is opinion and I have tried to keep it out.
best — the order this archive was captured in
Removed the staff name. Facilities and clinics can be named here; individuals cannot.
A beyond-use date derived from published stability data means something different from one assigned by default rule. Asking which is a fair question and the answer is usually available.
ask what the beyond-use date is based on
On concentration, which is where I see people actually get hurt.
A compounded vial can be filled at a different concentration from the branded product you were previously using. If you carry over your old arithmetic — same number of units, different mg/mL — you draw a different amount and may not notice for weeks.
Read the label every time you switch. Redo the arithmetic on paper. Write the concentration on the vial. It is the same habit c/reconstitution keeps preaching and this is the case where it actually bites.
Not convinced. You are comparing a compounded concentration with a branded one and assuming they match.
Potency and sterility testing on the finished preparation are separate from any certificate covering the starting material. Ask which you are being shown.
I would not read the price difference as a quality signal. Most of it is the consultation model, not the vial.
What did the intake actually ask you?
do not assume the concentration matches the branded product
a 503B has to register and report, so there is a paper trail to ask for
ask which facility, then ask for their testing
Paid noticeably more at one clinic than another for what turned out to be the same facility behind both.
the label on a compounded vial is a legal document, read it
I would not read the price difference as a quality signal.
This is the distinction the whole board runs on. Everything else follows from it.
Correcting my own comment: the shortage status changed in the interim, so the arrangement I described no longer applies.
shortage status changes and the whole arrangement changes with it
shortage status changes and the whole arrangement changes with it
usp_appendix is right about the concentration trap. It breaks arithmetic that has been reliable for months.
The shortage list is the legal hinge: the permissions that allow certain compounding to happen at scale are tied to a drug’s shortage status, which changes.
Salt form matters for mass: a preparation specified as one salt and dosed as the free base gives you a different amount of peptide for the same number on the label.
The five questions worth asking before you commit to any compounded arrangement.
Which facility, by name. Whether it is a 503A pharmacy or a 503B outsourcing facility. What concentration is on the label. What the beyond-use date is based on. Whether there is potency testing on the finished preparation rather than only on the starting material.
All five are answerable in one email and the pattern of what comes back is more informative than any of the individual answers. An organisation with a quality system finds these questions ordinary.
the pharmacy and the prescriber are two separate questions
if a clinic will not name the facility, that is your answer
salt forms are the recurring argument and the answer is boring
- 1I would not read the price difference as a quality signal. Most of it is the…12 comments in this branch · started by u/controversial_only